Key terms
About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BMRN news
Today
7:20am ET
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)
Today
5:27am ET
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), PTC Therapeutics (PTCT) and Teladoc (TDOC)
Today
1:57am ET
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Earnings and Voxzogo’s Growth Potential
Yesterday
9:31am ET
BioMarin price target raised to $85 from $83 at Scotiabank
Yesterday
7:56am ET
Oppenheimer Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
Yesterday
7:51am ET
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
Yesterday
7:33am ET
BioMarin price target lowered to $91 from $94 at Citi
Yesterday
7:32am ET
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Universal Health (UHS)
Yesterday
7:28am ET
Scotiabank Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
Yesterday
7:02am ET
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)
Apr 24
4:08pm ET
BioMarin raises FY24 adjusted EPS view to $2.75-$2.95 from $2.60-$280
Apr 24
4:05pm ET
BioMarin reports Q1 non-GAAP EPS 71c, consensus 34c
Apr 24
3:44pm ET
BioMarin options imply 5.4% move in share price post-earnings
Apr 24
8:00am ET
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and BioMarin Pharmaceutical (BMRN)
Apr 24
5:37am ET
Buy Rating Affirmed on BioMarin Amid Voxzogo Success and Promising Growth Outlook
Apr 22
8:28am ET
BioMarin Pharmaceutical (BMRN) Receives a Buy from Piper Sandler
Apr 22
7:17am ET
BioMarin price target raised to $110 from $100 at Cantor Fitzgerald
Apr 15
7:35pm ET
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market Expectations
Apr 12
11:25am ET
BioMarin participates in a conference call with JPMorgan.
Apr 12
8:33am ET
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)
Apr 12
4:55am ET
BioMarin participates in a conference call with JPMorgan.
Apr 11
5:29pm ET
BioMarin participates in a conference call with JPMorgan.
Apr 08
10:40pm ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
Mar 26
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)
Mar 13
8:25am ET
Buy Rating Justified by Voxzogo’s Efficacy in Hypochondroplasia Treatment: A Deep Dive into BioMarin Pharmaceutical’s Clinical Data
Mar 13
7:11am ET
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)
Mar 12
8:36am ET
BioMarin presents new data for Voxzogo in achondroplasia and achondroplasia
Mar 11
3:35pm ET
Fly Insider : Echostar, Dell among week’s notable insider trades
Mar 08
5:39am ET
Wells Fargo Remains a Buy on BioMarin Pharmaceutical (BMRN)
Mar 07
6:58pm ET
BioMarin exec Fuchs sells 35,341 common shares
Mar 07
8:32am ET
BioMarin appoints Cristin Hubbard as Chief Commercial Officer
No recent press releases are available for BMRN
BMRN Financials
Key terms
Ad Feedback
BMRN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BMRN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
